MedTrace Logo

Biomarkers for Identification of COVID-19 Infection

NCT04322513 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2021-10-25

No results posted yet for this study

Summary

Acute lung injury represents the most severe form of the viral infection sustained by coronavirus disease 2019 (Covid-19) also named as SARS-CoV-2, a new virus emerged in December 2019 in Wuhan (China). The diagnosis is clinical and patients develop flu-like syndrome with fever and cough; patients with clinical symptoms can perform a swab test, including molecular and/or antigen swab, for diagnosis of positivity to Covid-19. Even if diagnosis and treatment are well described, to date, this viral pandemic infection induces an increased mortality in the world. The aim of the present project is to evaluate specific biomarkers that could be used for patient stratification and for tailor therapy in COVID-19 infected patients.

Conditions

  • Coronavirus

Interventions

DIAGNOSTIC_TEST

Biomarkers expression

Evaluation in biomarkers expression between 2 groups

Sponsors & Collaborators

  • Azienda Ospedaliera Pugliese Ciaccio

    collaborator OTHER

  • Azienda Ospedaliera Universitaria Mater Domini, Catanzaro

    collaborator OTHER

  • University of Catanzaro

    lead OTHER

Eligibility

Min Age
14 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-24
Primary Completion
2021-06-30
Completion
2022-12-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04322513 on ClinicalTrials.gov